The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

eventually invading and occupying large areas of the lung. It is from these cells, which express a gene called Krt5 that ...

We are excited to share that our MRD platform was selected for the important UMBRELLA trial being run out of Institute Gustave Roussy on approximately 700 patients with non-small cell lung cancer ...

There are still many unanswered questions on the use of EGFR treatment in NSCLC Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in non-small cell lung ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Low-dose computed tomography is more sensitive than chest radiography in detecting lung metastases or second primary lung cancer in patients with HNSCC.

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Raymond Osarogiagbon, MD, shares practical strategies for clinicians and health systems to boost lung cancer screening rates among eligible patients.

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system.